Mario Alberto Accardi - Sep 9, 2025 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
President, Orexin Program
Signature
/s/ Raphael Deferiere, attorney-in-fact
Stock symbol
CNTA
Transactions as of
Sep 9, 2025
Transactions value $
-$99,950
Form type
4
Date filed
9/11/2025, 05:45 PM
Previous filing
Aug 1, 2025
Next filing
Sep 16, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Accardi Mario Alberto President, Orexin Program C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE, UNITED KINGDOM /s/ Raphael Deferiere, attorney-in-fact 2025-09-11 0002074392

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNTA Ordinary Shares Options Exercise $40.1K +5K +2.41% $8.01 213K Sep 9, 2025 Direct F1
transaction CNTA Ordinary Shares Sale -$140K -7K -3.29% $20.00 206K Sep 9, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNTA Share Option (right to buy) Options Exercise $0 -5K -12.5% $0.00 35K Sep 9, 2025 Ordinary Shares 5K $8.01 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 14, 2025.
F3 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2024.

Remarks:

Exhibit 24.2 - Substitute Power of Attorney